Santoni, Natália, et al. “Cost-Effectiveness of Afatinib Versus Pemetrexed Plus Cisplatin, Erlotinib and Gefitinib As First Line Treatment in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor Mutation (EFGR+) Non-Small Cell Lung Cancer in the Brazil”. Jornal Brasileiro De Economia Da Saúde, vol. 9, nº 1, abril de 2017, p. 73-82, doi:10.21115/JBES.v9.n1.p73-82.